Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

已完结 10 由易只烊发布于 2024/11/7 15:49:48

DOI:10.1016/s0140-6736(23)02190-6
作者：Inder Kaul, Sharon Sawchak, Christoph U Correll, Rishi Kakar, Alan Breier, Haiyuan Zhu, Andrew C Miller, Steven M Paul, Stephen K Brannan
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundNew treatments with new mechanisms are urgently needed for people with schizophrenia. Xanomeline is a dual M1 and M4-preferring muscarinic receptor agonist that does not block D2 d

应助信息

6小时前

小丹

e59de0c49cdc11efacdd34735aa3bc31.pdf 已采纳

6小时前

Book学术机器人

2024/11/7 15:49:48 未找到该文献，机器人已退出，请等待人工下载

2024/11/7 15:49:48 Book学术AI机器人收到请求，开始寻找文献

2024/11/7 15:49:48 已向机器人发送请求

6小时前

易只烊发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:知网Langendorff心脏灌流技术(针对心肌缺血再灌注)的应用和发展